Treatment of infections of skin and skin structures, bronchitis, pharyngitis, tonsillitis, and otitis media caused by susceptible strains of specific microorganisms.
Adults: PO 250 to 500 mg every 12 to 24 h.
Children 6 mo to 12 yr of age: PO 7.5 to 15 mg/kg every 12 h.
Hypersensitivity to cephalosporins.
Use Cautiously in:
CNS: Headache, dizziness; fatigue; paresthesia; confusion; nervousness; sleeplessness; insomnia.
GI: Nausea; vomiting; diarrhea; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis.
GU: Genital pruritus; vaginitis; renal function impairment.
HEMA: Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; decreased platelet function; anemia; aplastic anemia; hemorrhage.
HEPA: Hepatic function impairment; cholestatic jaundice; abnormal LFT results.
OTHER: Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis; candidal overgrowth; serum sickness–like reactions (eg, skin rashes, polyarthritis, arthralgia, fever).
Inhibition of renal excretion of cefprozil.
Therapeutic Classification: anti-infectives
Pharmacologic Classification: second generation cephalosporins
Absorption: Well absorbed following oral administration.
Distribution: Widely distributed. Enters breast milk in low concentrations.
Metabolism/Excretion: Excreted primarily unchanged by the kidneys.
Half-life: 90 min (increased in renal impairment).
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal